Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. Summary
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
24.25(c) 24.25(c) 25.5(c) 23.9(c) 21.85(c) Last
14 026 10 180 19 964 35 246 29 279 Volume
-0.41% 0.00% +5.15% -6.27% -8.58% Change
More quotes
Estimated financial data (e)
Sales 2021 33,7 M 38,1 M 38,1 M
Net income 2021 -20,8 M -23,5 M -23,5 M
Net cash position 2021 18,5 M 20,9 M 20,9 M
P/E ratio 2021 -19,2x
Yield 2021 -
Sales 2022 51,9 M 58,7 M 58,7 M
Net income 2022 -14,9 M -16,8 M -16,8 M
Net Debt 2022 14,8 M 16,7 M 16,7 M
P/E ratio 2022 -119x
Yield 2022 -
Capitalization 358 M 404 M 404 M
EV / Sales 2021 10,1x
EV / Sales 2022 7,17x
Nbr of Employees 29
Free-Float 70,0%
More Financials
Company
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline... 
More about the company
Ratings of ABIVAX
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ABIVAX
12/02GLOBAL MARKETS LIVE : Hermès, Walt Disney, Apple, Novartis, Square...
12/02Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical te..
AQ
12/02Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerabil..
AQ
12/02Abivax Gets US FDA Feedback, Guidance On Late-Stage Trial For Ulcerative Colitis Therap..
MT
12/01Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical te..
EQ
12/01Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical..
CI
12/01Abivax's Liver Cancer Combo Shows Signs Of Clinical Benefit In Early-Stage Study
MT
11/30Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerabil..
EQ
10/21Certain Ordinary Shares of ABIVAX Soci?t? Anonyme are subject to a Lock-Up Agreement En..
CI
10/19ABIVAX : Prepares Third Phase Of Ulcerative Colitis Drug Trials
MT
10/18ABIVAX : ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance t..
PU
10/18ABIVAX : ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance T..
EQ
10/18Abivax Soci?t? Anonyme Provides Reports of Abivax's Phase 2B Maintenance Trial in Ulcer..
CI
09/30ABIVAX : announces the release of its half-year financial report 2021
PU
09/30ABIVAX : announces the release of its 2021áhalf-year financial report
EQ
More news
News in other languages on ABIVAX
12/02Un pas en avant, deux pas en arrière
12/02EN DIRECT DES MARCHES : Safran, Hermès, Danone, Capgemini, Air France-KLM, Apple, Disney....
12/02Abivax reçoit les commentaires et les conseils de la FDA américaine sur l'essai de phas..
12/01Abivax reçoit la réponse de la FDA afin d'avancer le programme clinique de phase 3 d'AB..
12/01Abivax erhält Feedback der US-Amerikanischen Zulassungsbehörde mit Guidance zur Überfüh..
More news
Chart ABIVAX
Duration : Period :
ABIVAX Technical Analysis Chart | ABVX | FR0012333284 | MarketScreener
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 21,85 €
Average target price 63,56 €
Spread / Average Target 191%
EPS Revisions
Managers and Directors
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ABIVAX-30.52%442
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745